Floatz logo

INTERFERON-ALFA-2A

Adenocarcinoma

Novartis Pharmaceuticalsprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Adenocarcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 4BBB
Carboplatin
Blueprint Medicines Corporation
Phase 4BBB
Irinotecan
University of Chicago
Phase 2BBB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

INTERFERON-ALFA-2A is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
kidney cancerDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →